Advances in  identification and treatment of refractory gastroesophageal reflux disease#br#

doi:10.3969/j.issn.1004-583X.2017.01.003

Clinical Focus

Previous Articles Next Articles

Advances in identification and treatment of refractory gastroesophageal reflux disease#br#

1.Department of Gastroenterology， the Third Hospital of Hebei Medical University，
Shijiazhuang 050051， China; 2. Department of Gastroenterology， the Second Hospital of
Hebei Medical University， Shijiazhuang 050051， China

Online:2017-01-05 Published:2017-01-12
Contact: Corresponding author: Bai Wenyuan， Email: wenyuanbai@medmail.com.cn

Abstract

Abstract: Refractory gastroesophageal reflux disease (RGERD) refers to the use of the standard dose of proton pump inhibitor (PPI) for eight weeks， reflux symptoms still remain no remission of gastroesophageal reflux disease. Symptoms of RGERD are characterized by persistent severe and frequent regurgitation after treatment with standard PPI. RGERD accounts for 10%40% of GERD， while 50% of RGERD is functional heartburn， which is the main source of PPI failure. RGERD is often associated with nonacid reflux. In patients with GERD who failed twice daily PPI therapy， the association of nonacid reflux with symptoms was much higher than that of acid reflux. The mechanism of RGERD is summarized as two aspects: PPI treatment failure and PPI resistance. RGERD diagnosis and treatment of the current AsiaPacific consensus indicates that none of the drugs can solve the failure of PPI treatment， a specific analysis of each RGERD etiology is necessary so as to take individual and reasonable treatment.

Key words: gastroesophageal reflux, proton pump inhibitors, consensus

Bai Yan1， Bai Wenyuan2. Advances in identification and treatment of refractory gastroesophageal reflux disease#br#[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2017.01.003.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2017.01.003

https://huicui.hebmu.edu.cn/EN/Y2017/V32/I1/9

[1]	Huang Yehong, Liu Gaifang, Xin Chenxi, Zhao Yunhong, Wu Jing. Searching for an optimal therapy for H.pylori eradication: High-dose proton-pump inhibitor dual therapy vs. bismuth-containing quadruple therapy [J]. Clinical Focus, 2022, 37(3): 230-233.
[2]	Song Yiran, Liang Xiaonan, Li Chenyang, Zhang Xiaolan. Interpretation on Chinese Expert Consensus of Irritable Bowel Syndrome in 2020 [J]. Clinical Focus, 2021, 36(7): 628-631.
[3]	Lei Lingyan, Guo Huifang. Progress in standardized diagnosis and treatment of spondyloarthritis [J]. Clinical Focus, 2019, 34(4): 299-305.
[4]	Guo Yahui, Niu Weiwei, Zhang Xiaolan. Interpretation of the consensus on diagnosis and management of inflammatory bowel disease(Beijing, 2018) from the perspective of diagnosis of Crohn's disease [J]. Clinical Focus, 2018, 33(12): 1077-1079,1082.
[5]	Liang Xiaonan, Yin Fengrong, Zhang Xiaolan. Interpretation of the consensus on diagnosis and management of inflammatory bowel disease (Beijing, 2018) from the perspective of diagnosis of ulcerative colitis [J]. Clinical Focus, 2018, 33(11): 987-990.
[6]	Han Ying. Current management of noncardiac chest pain [J]. Clinical Focus, 2017, 32(1): 50-53.
[7]	Ding Yu， Yan Xiue. Research progress of relationship between eosinophilic esophagitis and gastroesophageal reflux disease#br# [J]. Clinical Focus, 2017, 32(1): 42-45.
[8]	Su Shaohui. Psychosomatic factors and treatment of gastroesophageal reflux disease#br# [J]. Clinical Focus, 2017, 32(1): 37-41.
[9]	Liu Gaifang. Helicobacter pylori infection and gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 33-36.
[10]	Wu Jimin. Discussion of relevant issues about surgical treatment on gastroesophageal reflux disease#br# [J]. Clinical Focus, 2017, 32(1): 28-32.
[11]	Jiang Wenjun， Zhou Liya. Endoscopic therapy of gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 22-27,32.
[12]	Han Fei， Zhang Xiaolan. Advances in drug therapy of gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 17-21.
[13]	Niu Weiwei， Yin Fengrong. Advances in diagnosis of gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 13-16,21.
[14]	Han Ying. Biomarkers of gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 5-8,12.
[15]	Zhang Ling，Zou Duowu. Epidemiology and risk factors of gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 1-4.

Advances in identification and treatment of refractory gastroesophageal reflux disease#br#

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments